Last €0.38 EUR
Change Today -0.02 / -5.00%
Volume 6.9K
MERR On Other Exchanges
Symbol
Exchange
Dublin
As of 12:10 PM 10/2/14 All times are local (Market data is delayed by at least 15 minutes).

merrion pharmaceuticals plc (MERR) Snapshot

Open
€0.38
Previous Close
€0.40
Day High
€0.38
Day Low
€0.38
52 Week High
03/31/14 - €0.62
52 Week Low
09/19/14 - €0.38
Market Cap
7.0M
Average Volume 10 Days
9.6K
EPS TTM
€-0.09
Shares Outstanding
18.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MERRION PHARMACEUTICALS PLC (MERR)

Related News

No related news articles were found.

merrion pharmaceuticals plc (MERR) Related Businessweek News

No Related Businessweek News Found

merrion pharmaceuticals plc (MERR) Details

Merrion Pharmaceuticals plc is engaged in the development of pharmaceutical products primarily in Europe and the United States. The company develops oral forms of drugs, such as tablets and capsules that have poor absorption and are given by injection. Its product pipeline includes Orazol, an oral zoledronic acid tablet, which is in Phase III clinical development for the treatment of metastatic bone disease and breast cancer; Almerol, a dosage form of alendronate that is in Phase I/II clinical development for osteoporosis; Acyline, an oral GnRH antagonist that uses GIPET technology for treating oncology and other indications; and MER-102, a development stage product for the treatment of deep vein thrombosis. The company also has two license agreements with Novo Nordisk A/S to develop and commercialize oral forms of Novo Nordisk’s insulin and GLP-1 using its proprietary GIPET technology, as well collaborations with pharmaceutical companies, such as Ferring Pharmaceuticals, Rebel Pharmaceuticals, and others. Merrion Pharmaceuticals plc was founded in 2003 and is based in Dublin, Ireland.

1 Employees
Last Reported Date: 06/18/14
Founded in 2003

merrion pharmaceuticals plc (MERR) Top Compensated Officers

Consultant
Total Annual Compensation: €185.4K
Compensation as of Fiscal Year 2013.

merrion pharmaceuticals plc (MERR) Key Developments

Merrion Pharmaceuticals plc Announces Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2014

Merrion Pharmaceuticals plc announced unaudited consolidated earnings results for the six months ended June 30, 2014. For the six months, revenue from continuing operations was €995,793 against €995,374 a year ago. Loss from operating activities continuing operations was €53,644 against profit from operating activities ­continuing operations was €240,107 a year ago. Loss before income tax was €507,361 against €131,432 a year ago. Net loss for the period ­all attributable to equity holders of the company was €507,361 against €131,432 a year ago. Basic and diluted net loss per ordinary share was €2.76 against €0.73 a year ago. Net cash provided by operating activities was €242,932 against net cash used in operations of €195,884 a year ago.

Merrion Pharmaceuticals plc to Report First Half, 2014 Results on Sep 29, 2014

Merrion Pharmaceuticals plc announced that they will report first half, 2014 results on Sep 29, 2014

Hovione and Merrion Pharmaceuticals Announce Strategic Partnership on Use of Merrion's GIPET Technology

Hovione and Merrion Pharmaceuticals announced that they have concluded a strategic partnership directed to the use of Merrion's patented GIPET absorption enhancing technology by Hovione clients. Hovione will add its commercial reach and technical expertise to generate new products where the use of absorption enhancement through GIPET is appropriate. Hovione and Merrion Pharmaceuticals have already established a cooperative relationship on technical issues relating to GIPET manufacture, and the agreement provides for the companies to collaborate on the feasibility assessment of GIPET with development compounds introduced by Third Parties. Subject to a decision to proceed, separate technology and manufacturing agreements may be negotiated with the Third Party. In this way Hovione is able to leverage its expertise and international manufacturing capability in order to supply new products from clinical trials to commercialization. In its turn Merrion Pharmaceuticals is positioned to add to its current licenses with external development and marketing partners while keeping operational overheads to a minimum.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MERR:ID €0.38 EUR -0.02

MERR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MERR.
View Industry Companies
 

Industry Analysis

MERR

Industry Average

Valuation MERR Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERRION PHARMACEUTICALS PLC, please visit www.merrionpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.